The Silab group is well-known among cosmetic brands for their plant-derived actives. They have recently decided to initiate a diversification phase by inaugurating a new department, Silab Softcare, which will launch a first active to target the treatment of atopic skins intended for the dermocosmetics and dermatology markets.
In more than thirty years of existence, Silab, a French family company, has become an expert in cosmetic actives derived from plants and biotechnologies, and now covers all the main themes related to skin and hair care. The group counts 260 employees and its turnover reaches 40 million euros, including 60% abroad, 20% of which they reinvest in research.
Silab is gradually gaining a new dimension, by turning towards damaged or weakened skins, with a new department, Silab Softcare, meant to ‘develop, produce, and market innovative natural actives specially designed to address dermatological disorders.’
After five years of work with a group of dedicated researchers using tools and technologies from the health sector, the in-depth study of skin ecosystems, the development of in vitro and in vivo models… Silab Softcare was able to market the first active derived from this new approach: AD-RESYL®.
First target: atopic skins
Atopy is a chronic and inflammatory skin pathology. It concerns 15 to 20% of children, but also 1 to 3% of adults. This skin disease is relentlessly spreading all across the world, and is becoming a public health issue. Indeed, on top of hereditary factors, environmental issues are involved, like pollution (in particular in Asian …
